In agreement, the A2AR antagonists produce antiparkinsonian actions which can involve the blockade of the A2AR protomer in the A2AR-D2R complex, especially in view of the reduction of the extracellular DA levels in Parkinson’s disease (Surmeier et al., 2014). This evidence concerns the gene DRD2 and Parkinson disease.